PLEOTROPIC CARDIOPROTECTIVE EFFECTS OF ERYTHROPOIETIN

anemia, chronic kidney disease, erythropoietin, heart chronic failure, myocardial infarction

1. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71(2):524-527

2. Koury ST, Bondurant MC, Koury MJ, Semenza G. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77(11):2497-2503

3. Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998;13[suppl]:23-27

4. Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998;13 [suppl 2]: 3–8

5. Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100 (20):11612-11617

6. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteineproteases. Circulation 2002; 106 (23): 2973–2979

7. Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99(4):2258-2263

8. Brines M, Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70(2):246-250

9. Miki T, Miura T, Yano T et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006;317(1):68-75

10. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt8):1281-1283

11. Fisher J W. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003;228(1):1–14

12. Schwartzenberg S, Ben-Shoshan J, Keren G et al. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Expert Rev Cardiovasc Ther 2006; 4(1): 41-50

13. Joyeux-Faure M, Ramond A, Beguin PC et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 2006;20(1):51-56

14. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther2005;19(5):333-336

15. George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner.Cardiovasc Res 2005;68(2):299-306

16. Akimoto T, Kusano E, Inaba T et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000; 58(1):269–282

17. Jaquet K, Krause K, Tawakol-Khodai M et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64(2):326–333

18. Carlini RG, Alonzo EJ, Dominguez J et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55(2):546–553

19. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47(3):740–745

20. Hirata A, Minamino T, Asanuma H et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48(1):176-184

21. Horl WH, Ertl G. Anaemia and the heart. Eur J Clin Invest 2005;35 [Suppl 3]:20-25

22. Xu B, Dong GH, Liu H et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 2005; 35(2):161-168

23. Guijarro C, Egido J. Transcription factor kappa B (NF-кB) and renal disease. Kidney Int 2001;59(2):415-424

24. Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316(3): 999-1005

25. Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 2005;46(2):211-215

26. van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46(1):125-133

27. Spandou E, Tsouchnikas I, Karkevelas G et al. Erythropoietin attenuated renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006;21(2):330-336

28. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signalling cascades. Nature 2001;412(6847):641–647

29. Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308(4):990–994

30. Rafiee P, Shi Y, Su J et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100 (3): 187-197

31. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22(5):503-514

32. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63(2):208-216

33. Guglin ME, Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 2006;14(4):200-204

34. Tada H, Kagaya Y, Takeda M et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006;71(3):466-477

35. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005;42(5-6):233-241

36. Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation2003;108(1):79–85

37. Olea FD, Vera Janavel G et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol2006;47(6):736-741

38. Li Y, Takemura G, Okada H et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71 (4):684-694

39. Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113(4):535-453

40. Noiri E, Nagano N, Negishi K et al. Efficacy of Darbepoetin in Doxorubicin-Induced Cardiorenal Injury in Rats. Nephron Exp Nephrol 2006;104(1):e6-e14

41. Саенко ЮВ, Шутов АМ, Напалкова СМ, Селиванова ОС. Эритропоэтин снижает проявления оксидативного стресса, индуцированного доксорубицином, в почках крыс. Нефрология2005;9(2):96-100

42. Lewis BS, Karkabi B, Jaffe R et al. Anaemia and heart failure: statement of the problem. Nephrol Dial Transplant 2005; 20 [Suppl 7]:3-6

43. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775-1780

44. Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2):294-299

45. Silverberg DS, Wexler D, Iaina A et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38 (2): 295-310

46. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;(9)3:7-15

47. George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestiv heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165(11):1304-1309

48. Wexler D, Silverberg D, Blum M et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant 2005;20 [Suppl 7]:11-15

49. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004;19[Suppl 2]

50. Пересмотренные Европейские рекомендации по оптимальной практике лечения анемии у пациентов с хронической почечной недостаточностью. Анемия 2005;3:6-60

51. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002;61[Suppl 80]:35–38

52. Hampl H, Hennig L, Rosenberger C et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25(3):211-220

53. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35(2):250–256

54. Manolis AS, Tzeis S, Triantafyllou K et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(5):355-375

55. Kirkpantur A, Kahraman S, Yilmaz R et al. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters. Artif Organs 2005;29(12):965-972

56. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46(5):799-811

57. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16(7):2180-2189

58. Coussons PJ, Baig S, Fanutti C, Grant R. Novel tissue remodelling roles for human recombinant erythropoietin. Biochem Soc Trans 2005;33(5):1129-1130

59. Anton Martinez J, Ojeda Ortego J, Gonzalez Blanco P et al. Increased levels of erythropoietin in the initial phase of acute myocardial infarction. An Med Interna 1997;14(9):459-461

60. Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45(9):1406-1412

61. Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20 (2):135-141

62. Shin DH, Kwon YI, Choi SI et al. Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: report of two cases. Basic Clin Pharmacol Toxicol 2006; 98 (2): 222-224

63. Vasu S, Kelly P, Lawson WE. Anemia in heart failure-a concise review. Clin Cardiol 2005;28(10):454-458